Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018

  • ID: 4580442
  • Report
  • 194 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Columbia University
  • Emergent BioSolutions Inc
  • Laboratorios Andromaco
  • Mithra Pharmaceuticals SA
  • RDD Pharma Ltd
  • MORE
Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018

Summary

The Medical Devices sector report, “Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transmucosal Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transmucosal Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by The team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Transmucosal Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transmucosal Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transmucosal Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Columbia University
  • Emergent BioSolutions Inc
  • Laboratorios Andromaco
  • Mithra Pharmaceuticals SA
  • RDD Pharma Ltd
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Transmucosal Drug Delivery Overview

3 Products under Development
3.1 Transmucosal Drug Delivery - Pipeline Products by Stage of Development
3.2 Transmucosal Drug Delivery - Pipeline Products by Segment
3.3 Transmucosal Drug Delivery - Pipeline Products by Territory
3.4 Transmucosal Drug Delivery - Pipeline Products by Regulatory Path
3.5 Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date
3.6 Transmucosal Drug Delivery - Ongoing Clinical Trials

4 Transmucosal Drug Delivery - Pipeline Products under Development by Companies
4.1 Transmucosal Drug Delivery Companies - Pipeline Products by Stage of Development
4.2 Transmucosal Drug Delivery - Pipeline Products by Stage of Development

5 Transmucosal Drug Delivery Companies and Product Overview
5.1 AcelRx Pharmaceuticals Inc Company Overview
5.2 Albert Einstein College of Medicine Company Overview
5.3 Allergan Plc Company Overview
5.4 Amphastar Pharmaceuticals Inc Company Overview
5.5 BeFree! Company Overview
5.6 Bespak Europe Ltd Company Overview
5.7 Biorings LLC Company Overview
5.8 BMG Pharma srl Company Overview
5.9 Columbia University Company Overview
5.10 Combinent BioMedical Systems Inc Company Overview
5.11 Conrad Company Overview
5.12 Corium International Inc Company Overview
5.13 Dare Bioscience Inc Company Overview
5.14 Dermtreat ApS Company Overview
5.15 Emergent BioSolutions Inc Company Overview
5.16 Evestra Inc Company Overview
5.17 Evofem Biosciences Inc Company Overview
5.18 Ferring Pharmaceuticals A/S Company Overview
5.19 Ghent University Company Overview
5.20 Karessa Pharma AB Company Overview
5.21 Kytogenics Pharmaceuticals Inc Company Overview
5.22 Laboratoire HRA Pharma SAS Company Overview
5.23 Laboratorios Andromaco Company Overview
5.24 McNeil AB Company Overview
5.25 Merck & Co Inc Company Overview
5.26 Merck Serono SA Company Overview
5.27 Merck Sharp & Dohme Ltd Company Overview
5.28 Mercy Research and Development Company Overview
5.29 Mithra Pharmaceuticals SA Company Overview
5.30 Mystic Pharmaceuticals Inc Company Overview
5.31 Nanosys Inc Company Overview
5.32 NorInvent AB Company Overview
5.33 Novus Therapeutics Inc Company Overview
5.34 Oak Crest Institute of Science Company Overview
5.35 Opiant Pharmaceuticals Inc Company Overview
5.36 OptiNose AS Company Overview
5.37 RDD Pharma Ltd Company Overview
5.38 Rhinomed Ltd Company Overview
5.39 Shin Nippon Biomedical Laboratories Ltd Company Overview
5.40 Sonoma Pharmaceuticals Inc Company Overview
5.41 Texas Tech University Company Overview
5.42 The Hong Kong University of Science and Technology Company Overview
5.43 Therakind Ltd Company Overview
5.44 UCB SA Company Overview
5.45 University of North Carolina at Chapel Hill Company Overview
5.46 University of South Florida Company Overview
5.47 University of Texas at Austin Company Overview
5.48 University of the Witwatersrand Company Overview
5.49 University of Washington Company Overview
5.50 Yale School of Medicine Company Overview

6 Transmucosal Drug Delivery- Recent Developments
6.1 Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer
6.2 Jun 04, 2018: Dare Bioscience Appoints Mary Jarosz To Global Head Of Regulatory Affairs
6.3 Jun 04, 2018: RDD Pharma Names Dr. Mark Sirgo As Chairman Of The Board Of Directors
6.4 May 29, 2018: Egalet Announces Large Regional Plan to Cover SPRIX Nasal Spray
6.5 May 29, 2018: ADAPT Pharma Launches New Online Platform for NARCAN
6.6 May 28, 2018: Update on Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Opportunity
6.7 May 24, 2018: AcelRx announces FDA acceptance of NDA for DSUVIA
6.8 May 21, 2018: Summit Medical Group Research Aids in FDA Approval of Drug for Nasal Polyps
6.9 May 18, 2018: Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting
6.10 May 15, 2018: Dare Bioscience Announces Trial Initiation for Ovaprene Non-Hormonal Monthly Contraceptive Candidate
6.11 May 14, 2018: Corium Announces Second Quarter Fiscal 2018 Financial Results
6.12 May 10, 2018: BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update
6.13 May 09, 2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program
6.14 May 09, 2018: AcelRx resubmits New Drug Application for DSUVIA
6.15 May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
6.16 May 08, 2018: Dare Bioscience Expands Leadership Team, Appointing John Fair to Chief Business Officer
6.17 May 08, 2018: Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
6.18 May 07, 2018: Optinose Provides Update on XHANCE
6.19 May 07, 2018: BioDelivery Sciences Names Herm Cukier As Chief Executive Officer
6.20 May 01, 2018: Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria
6.21 Apr 30, 2018: AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
6.22 Apr 30, 2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability
6.23 Apr 30, 2018: Dare Bioscience announces funding award to further the development of Ovaprene from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
6.24 Apr 26, 2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations
6.25 Apr 26, 2018: Consort Medical: Director Declaration
6.26 Apr 25, 2018: Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego
6.27 Apr 25, 2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities
6.28 Apr 16, 2018: AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
6.29 Apr 11, 2018: Jessica Grossman Joins Dare Bioscience Board of Directors
6.30 Apr 09, 2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies
6.31 Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory
6.32 Apr 05, 2018: Naloxone Nasal Spray now available to First Nations and Inuit through Non-Insured Health Benefits program
6.33 Apr 05, 2018: CVS Health Expands Efforts to Educate Patients about Naloxone
6.34 Apr 04, 2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia
6.35 Apr 02, 2018: Intersect ENT Announces Launch of SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
6.36 Mar 27, 2018: AcelRx Pharmaceuticals Names John Saia As General Counsel
6.37 Mar 20, 2018: Mithra And Mayne Pharma Vaginal Contraceptive Ring Accepted For Filing By FDA
6.38 Mar 19, 2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities
6.39 Mar 16, 2018: Intention to grant for the XtriG-patent in Europe
6.40 Mar 16, 2018: BioDelivery Sciences Announces Fourth Quarter and Full-Year 2017 Financial Results
6.41 Mar 13, 2018: Injectable Medication Shortage is Affecting Terminally Ill Patients
6.42 Mar 08, 2018: Notice of Allowance for XtriG patent in the USA
6.43 Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results
6.44 Mar 07, 2018: Ontario Government takes significant action to address opioid crisis; NARCAN Nasal Spray to be made available to all Ontarians free of charge through pharmacies
6.45 Mar 06, 2018: High uptake and use of vaginal ring for HIV prevention observed in open-label study
6.46 Feb 27, 2018: Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
6.47 Feb 22, 2018: Teleflex Highlights LMA Gastro Airway Study, Which Shows Efficacy for Use in Upper Gastrointestinal Endoscopy
6.48 Feb 08, 2018: AptarGroup and Adapt Pharma Donate NARCAN Nasal Spray to Opioid Crisis Coalitions in Illinois
6.49 Feb 08, 2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose
6.50 Feb 08, 2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose
6.51 Feb 08, 2018: Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights
6.52 Feb 07, 2018: Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
6.53 Feb 06, 2018: BioDelivery Sciences Announces BELBUCA Patent Litigation Settlement Agreement with Teva
6.54 Jan 22, 2018: Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
6.55 Jan 11, 2018: Dermtreat Submits IND And CTA For Phase 2b Study
6.56 Jan 04, 2018: RDD Pharma Completes Enrollment in European Phase 3 Clinical Trial for Chronic Anal Fissure

7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact Us
7.4 Disclaimer

List of Tables
Table 1: Transmucosal Drug Delivery - Pipeline Products by Stage of Development
Table 2: Transmucosal Drug Delivery - Pipeline Products by Segment
Table 3: Transmucosal Drug Delivery - Pipeline Products by Territory
Table 4: Transmucosal Drug Delivery - Pipeline Products by Regulatory Path
Table 5: Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date
Table 6: Transmucosal Drug Delivery - Ongoing Clinical Trials
Table 7: Transmucosal Drug Delivery Companies - Pipeline Products by Stage of Development
Table 8: Transmucosal Drug Delivery - Pipeline Products by Stage of Development
Table 9: AcelRx Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: ARX-02 Sufentanil NanoTab BTP Management System - Product Status
Table 11: ARX-02 Sufentanil NanoTab BTP Management System - Product Description
Table 12: ARX-03 Sufentanil/Trazolam NanoTab - Product Status
Table 13: ARX-03 Sufentanil/Trazolam NanoTab - Product Description
Table 14: DSUVIA Single-Dose Applicator - Product Status
Table 15: DSUVIA Single-Dose Applicator - Product Description
Table 16: ZALVISO - Product Status
Table 17: ZALVISO - Product Description
Table 18: AcelRx Pharmaceuticals Inc - Ongoing Clinical Trials Overview
Table 19: ZALVISO - Treatment of Acute Post-operative Pain in Patients Undergoing Laparoscopic Colon Resections
Table 20: ZALVISO - Usability and Satisfaction Evaluation of Sufentanil Sublingual Patient-Controlled Analgesia After Elective Surgery With Moderate-to-Severe Postoperative Pain
Table 21: Albert Einstein College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table 22: Drug-Impregnated Intravaginal Ring - Product Status
Table 23: Drug-Impregnated Intravaginal Ring - Product Description
Table 24: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 25: Vaginal Ring Contraceptive - Product Status
Table 26: Vaginal Ring Contraceptive - Product Description
Table 27: Amphastar Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Intranasal Naloxone Spray - Product Status
Table 29: Intranasal Naloxone Spray - Product Description
Table 30: BeFree! Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Vaginal Drug Delivery System - Product Status
Table 32: Vaginal Drug Delivery System - Product Description
Table 33: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 34: NAS010 - Product Status
Table 35: NAS010 - Product Description
Table 36: NAS020 - Unidose Nasal Drug Delivery Device - Product Status
Table 37: NAS020 - Unidose Nasal Drug Delivery Device - Product Description
Table 38: NAS030 Nasal Device - Product Status
Table 39: NAS030 Nasal Device - Product Description
Table 40: Biorings LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Vaginal Ring - Product Status
Table 42: Vaginal Ring - Product Description
Table 43: BMG Pharma srl Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Isysin Hyper - Product Status
Table 45: Isysin Hyper - Product Description
Table 46: Isysin Iso - Product Status
Table 47: Isysin Iso - Product Description
Table 48: Columbia University Pipeline Products & Ongoing Clinical Trials Overview
Table 49: Focused Ultrasound - Intranasal Drug Delivery - Product Status
Table 50: Focused Ultrasound - Intranasal Drug Delivery - Product Description
Table 51: Combinent BioMedical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 52: Multi-Segmented Vaginal Ring - Product Status
Table 53: Multi-Segmented Vaginal Ring - Product Description
Table 54: Conrad Pipeline Products & Ongoing Clinical Trials Overview
Table 55: Triple Protection Vaginal Ring - Product Status
Table 56: Triple Protection Vaginal Ring - Product Description
Table 57: Vaginal Ring - HIV Protection - Product Status
Table 58: Vaginal Ring - HIV Protection - Product Description
Table 59: Corium International Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 60: Rapidly Dissolving Film - Product Status
Table 61: Rapidly Dissolving Film - Product Description
Table 62: Solid State Film - Product Status
Table 63: Solid State Film - Product Description
Table 64: Dare Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Intravaginal Ring - Product Status
Table 66: Intravaginal Ring - Product Description
Table 67: Ovaprene - Product Status
Table 68: Ovaprene - Product Description
Table 69: Dare Bioscience Inc - Ongoing Clinical Trials Overview
Table 70: Ovaprene - Post-coital Test (PCT) Clinical Study to Evaluate Safety and Efficacy of Ovaprene Non-hormonal Monthly Contraceptive Candidate
Table 71: Intravaginal Ring - A Phase I Clinical Study of JNP-0201
Table 72: Intravaginal Ring - A Phase I Clinical Study of JNP-0301
Table 73: Intravaginal Ring - Phase IIa Study of JNP-0101
Table 74: Intravaginal Ring - Phase III Study of JNP-0101
Table 75: Dermtreat ApS Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Rivelin Clobetasol Patch - Product Status
Table 77: Rivelin Clobetasol Patch - Product Description
Table 78: Dermtreat ApS - Ongoing Clinical Trials Overview
Table 79: Rivelin Clobetasol Patch - Phase IIb Clinical Study of Rivelin Clobetasol Patch in Treatment of Oral Lichen Planus (OLP)
Table 80: Emergent BioSolutions Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 81: Intranasal SIAN Device - Product Status
Table 82: Intranasal SIAN Device - Product Description
Table 83: Evestra Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 84: EVE112 - Vaginal Ring - Product Status
Table 85: EVE112 - Vaginal Ring - Product Description
Table 86: EVE116 - Product Status
Table 87: EVE116 - Product Description
Table 88: Progestin Vaginal Ring - Product Status
Table 89: Progestin Vaginal Ring - Product Description
Table 90: Vaginal Ring For Preterm Labor - Product Status
Table 91: Vaginal Ring For Preterm Labor - Product Description
Table 92: Evofem Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 93: Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR) - Product Status
Table 94: Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR) - Product Description
Table 95: Ferring Pharmaceuticals A/S Pipeline Products & Ongoing Clinical Trials Overview
Table 96: C-Vad Vaginal Insert - Product Status
Table 97: C-Vad Vaginal Insert - Product Description
Table 98: Premis Vaginal Insert - Product Status
Table 99: Premis Vaginal Insert - Product Description
Table 100: Ghent University Pipeline Products & Ongoing Clinical Trials Overview
Table 101: Controlled-Release System - Intra-Vaginal Delivery - Product Status
Table 102: Controlled-Release System - Intra-Vaginal Delivery - Product Description
Table 103: Karessa Pharma AB Pipeline Products & Ongoing Clinical Trials Overview
Table 104: K-01 - Product Status
Table 105: K-01 - Product Description
Table 106: K-02 - Product Status

List of Figures
Figure 1: Transmucosal Drug Delivery - Pipeline Products by Stage of Development
Figure 2: Transmucosal Drug Delivery - Pipeline Products by Segment
Figure 3: Transmucosal Drug Delivery - Pipeline Products by Territory
Figure 4: Transmucosal Drug Delivery - Pipeline Products by Regulatory Path
Figure 5: Transmucosal Drug Delivery - Pipeline Products by Estimated Approval Date
Figure 6: Transmucosal Drug Delivery - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AcelRx Pharmaceuticals Inc
  • Albert Einstein College of Medicine
  • Allergan Plc
  • Amphastar Pharmaceuticals Inc
  • BeFree!
  • Bespak Europe Ltd
  • Biorings LLC
  • BMG Pharma srl
  • Columbia University
  • Combinent BioMedical Systems Inc
  • Conrad
  • Corium International Inc
  • Dare Bioscience Inc
  • Dermtreat ApS
  • Emergent BioSolutions Inc
  • Evestra Inc
  • Evofem Biosciences Inc
  • Ferring Pharmaceuticals A/S
  • Ghent University
  • Karessa Pharma AB
  • Kytogenics Pharmaceuticals Inc
  • Laboratoire HRA Pharma SAS
  • Laboratorios Andromaco
  • McNeil AB
  • Merck & Co Inc
  • Merck Serono SA
  • Merck Sharp & Dohme Ltd
  • Mercy Research and Development
  • Mithra Pharmaceuticals SA
  • Mystic Pharmaceuticals Inc
  • Nanosys Inc
  • NorInvent AB
  • Novus Therapeutics Inc
  • Oak Crest Institute of Science
  • Opiant Pharmaceuticals Inc
  • OptiNose AS
  • RDD Pharma Ltd
  • Rhinomed Ltd
  • Shin Nippon Biomedical Laboratories Ltd
  • Sonoma Pharmaceuticals Inc
  • Texas Tech University
  • The Hong Kong University of Science and Technology
  • Therakind Ltd
  • UCB SA
  • University of North Carolina at Chapel Hill
  • University of South Florida
  • University of Texas at Austin
  • University of the Witwatersrand
  • University of Washington
  • Yale School of Medicine
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll